Brown Brothers Harriman & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Brown Brothers Harriman & Co’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-31	Closed	-$2K	–	862
2016 Q4	$2K	Hold	31	–	–	﹤0.01%	832
2016 Q3	$2K	Hold	31	–	–	﹤0.01%	751
2016 Q2	$2K	Buy	+31	New	+$2K	﹤0.01%	794
2015 Q2	–	Sell	-525	Closed	-$33K	–	789
2015 Q1	$33K	Sell	525 -3,545	-87%	-$197K	﹤0.01%	545
2014 Q4	$179K	Hold	4,070	–	–	﹤0.01%	362
2014 Q3	$230K	Buy	+4,070	New	+$205K	﹤0.01%	332

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Brown Brothers Harriman & Co's RARE Position: Q1 2017 in Review

Brown Brothers Harriman & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 31 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in RARE in Q3 2014 and held it in 6 quarters. The position peaked at $230K in Q3 2014. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

Brown Brothers Harriman & Co reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
Brown Brothers Harriman & Co sold 31 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $2K.
Brown Brothers Harriman & Co first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 6 quarters.
Brown Brothers Harriman & Co's Ultragenyx Pharmaceutical position peaked at $230K in Q3 2014.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2017, filed 12 May 2017.